AI Drugmaker Insilico Strikes $888 Million Cancer Drug Deal With Servier
00:00/00:00
Listen to this article
1x
Subscribe now
Listen to the full version
Listen to the full version
Insilico Medicine lists on the Hong Kong Stock Exchange on Dec. 30, 2025. Photo: VCG
Insilico Medicine Inc., an artificial intelligence-driven drug discovery firm, has struck a collaboration deal worth up to $888 million with French pharmaceutical company Servier, marking a major vote of confidence just days after its IPO on the Hong Kong Stock Exchange.
In a statement on Jan. 5, Insilico said the multi-year partnership aims to identify and develop new cancer therapies using its proprietary Pharma.AI platform. The deal includes up to $32 million in upfront and near-term milestone payments. Shares of Insilico jumped more than 5% on Jan. 7 to close above HK$40 ($5.1) each — a significant premium over its offering price of HK$24.05 set on Dec. 30.
You've accessed an article available only to subscribers
VIEW OPTIONS
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Subscribe to both Caixin Global and The Wall Street Journal — for the price of one.
- RELATED
Share this article
Open WeChat and scan the QR code
- DIGEST HUB
Digest Hub
Back
Explore the story in 30 seconds
- Insilico Medicine signed a collaboration with Servier worth up to $888 million to develop cancer drugs using its Pharma.AI platform, including $32 million in upfront and near-term payments.
- Insilico, listed in Hong Kong since Dec. 30, 2024, saw revenue rise to $85.8 million in 2024 but posted a $17.1 million net loss; first-half 2025 revenue dropped 54%.
- The firm’s lead AI-designed drug for pulmonary fibrosis has reached Phase II trials, with further studies set for 2026.
AI generated, for reference only
Who’s Who
- Insilico Medicine Inc.
- Insilico Medicine Inc. is an AI-driven drug discovery company that recently IPO'd on the Hong Kong Stock Exchange. They've secured an $888 million collaboration deal with Servier for cancer therapies, utilizing their Pharma.AI platform. Founded in 2014, Insilico uses AI to accelerate drug target discovery and molecular design, generating revenue through licensing and collaborations. Their lead candidate, ISM001_055, is the first AI-designed drug to reach Phase II trials globally.
- Servier
- Servier is a French pharmaceutical company that has partnered with Insilico Medicine Inc. in a collaboration valued at up to $888 million. This multi-year agreement aims to develop new cancer therapies using Insilico's AI platform. Servier will co-fund research and will be responsible for clinical trials and commercialization of the therapies.
- Exelixis Inc.
- Exelixis Inc. (益立迈) entered into a license agreement with Insilico Medicine in September 2023. This deal involved an upfront payment of $80 million from Exelixis to Insilico. This collaboration is highlighted as one of Insilico's high-profile partnerships, alongside agreements with Servier and Menarini Group.
- Menarini Group
- Menarini Group is a pharmaceutical company that has entered into multiple agreements with Insilico Medicine Inc. These agreements indicate a collaboration between the two entities, though specific details beyond their existence are not provided in the article.
- XtalPi Holdings Ltd.
- XtalPi Holdings Ltd. is an AI drug discovery company that went public in June 2024. It was the first AI drug discovery stock to be listed in Hong Kong, preceding its rival Insilico Medicine Inc.'s IPO.
AI generated, for reference only
What Happened When
- 2014：
- Insilico Medicine Inc. was founded.
- 2022：
- Insilico Medicine's revenue was $30.1 million.
- 2023-09：
- Insilico Medicine signed a license agreement with Exelixis Inc. worth $80 million upfront.
- Mid-2023：
- Insilico Medicine began the first of three filings for its Hong Kong IPO.
- 2024：
- Insilico Medicine's revenue reached $85.8 million and it posted a net loss of $17.1 million.
- 2024-06：
- Rival XtalPi Holdings Ltd. went public in Hong Kong, becoming the first listed AI drug discovery stock in the city.
- First half of 2025：
- Insilico Medicine's revenue fell 54% year-on-year to $27.5 million, turning from an $8 million profit in the same period of 2024 to a $19.2 million loss.
- 2025-12-30：
- Insilico Medicine debuted on the Hong Kong Stock Exchange, raising HK$2.3 billion, with an offering price of HK$24.05 per share.
- 2026-01-05：
- Insilico Medicine announced a multi-year partnership with Servier worth up to $888 million.
- 2026-01-07：
- Shares of Insilico Medicine jumped more than 5%, closing above HK$40 per share.
AI generated, for reference only
- MOST POPULAR
Sign in with Google
Sign in with Facebook
Sign in with 财新